MX351262B - Composicion para el transporte transdermico de agentes activos cationicos. - Google Patents

Composicion para el transporte transdermico de agentes activos cationicos.

Info

Publication number
MX351262B
MX351262B MX2010013853A MX2010013853A MX351262B MX 351262 B MX351262 B MX 351262B MX 2010013853 A MX2010013853 A MX 2010013853A MX 2010013853 A MX2010013853 A MX 2010013853A MX 351262 B MX351262 B MX 351262B
Authority
MX
Mexico
Prior art keywords
composition
cationic active
transdermal delivery
active agents
salt
Prior art date
Application number
MX2010013853A
Other languages
English (en)
Other versions
MX2010013853A (es
Inventor
Koch Andreas
Horstmann Michael
Sameti Mohammad
Schmitz Christoph
Original Assignee
Lts Lohmann Therapie Systeme Ag Star
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lts Lohmann Therapie Systeme Ag Star filed Critical Lts Lohmann Therapie Systeme Ag Star
Publication of MX2010013853A publication Critical patent/MX2010013853A/es
Publication of MX351262B publication Critical patent/MX351262B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
    • G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
    • G01N27/416—Systems
    • G01N27/447—Systems using electrophoresis

Abstract

La invención se refiere a una composición para el transporte transdérmico, en particular transporte transdérmico iontoforético, de al menos un agente activo catiónico o una sal del mismo, de manera que la composición comprenda al menos un agente activo catiónico o una sal del mismo, al menos una poliamina o/y una sal de poliamina, agua o bien una mezcla de disolvente acuoso, y opcionalmente uno o más aditivos. La invención se refiere además al uso de la composición en un método para administrar por vía transdérmica o iontoforética agentes activos catiónicos, y a un método para determinar las propiedades de permeación cutánea in vitro de una composición iontoforética que contenga agente activo.
MX2010013853A 2008-06-19 2009-06-16 Composicion para el transporte transdermico de agentes activos cationicos. MX351262B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13252708P 2008-06-19 2008-06-19
PCT/EP2009/004316 WO2009153019A1 (en) 2008-06-19 2009-06-16 Composition for transdermal delivery of cationic active agents

Publications (2)

Publication Number Publication Date
MX2010013853A MX2010013853A (es) 2011-03-15
MX351262B true MX351262B (es) 2017-10-06

Family

ID=40934213

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010013853A MX351262B (es) 2008-06-19 2009-06-16 Composicion para el transporte transdermico de agentes activos cationicos.

Country Status (16)

Country Link
US (2) US10881606B2 (es)
EP (2) EP3308777A1 (es)
JP (2) JP5620907B2 (es)
KR (1) KR101656537B1 (es)
CN (2) CN105456181A (es)
AU (1) AU2009259601B2 (es)
BR (1) BRPI0909936B1 (es)
CA (1) CA2728975C (es)
ES (1) ES2639576T3 (es)
IL (1) IL210080A (es)
MX (1) MX351262B (es)
NZ (1) NZ590510A (es)
PL (1) PL2285362T3 (es)
RU (1) RU2517241C2 (es)
WO (1) WO2009153019A1 (es)
ZA (1) ZA201007576B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8366600B2 (en) 2008-06-19 2013-02-05 Nupathe Inc. Polyamine enhanced formulations for triptan compound iontophoresis
WO2015058080A1 (en) * 2013-10-17 2015-04-23 Causwave Inc. System and method for transdermal dialysis
JP6564369B2 (ja) 2013-12-09 2019-08-21 デュレクト コーポレイション 薬学的活性剤複合体、ポリマー複合体、ならびにこれらを伴う組成物及び方法
WO2017119520A1 (ko) * 2016-01-05 2017-07-13 바이오센서연구소 주식회사 역전기 투석을 이용한 마스크팩 및 그를 포함하는 키트
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
BR112020010195A2 (pt) 2017-12-20 2020-11-03 Lts Lohmann Therapie-Systeme Ag composição frigoestável para distribuição transdermal iontoforética de um composto de triptano
CN111491619A (zh) 2017-12-20 2020-08-04 Lts勒曼治疗系统股份公司 用于离子电渗透皮递送曲坦化合物的耐低温的组合物
US11766558B2 (en) 2018-07-30 2023-09-26 Compass Health Brands Corp. Biomedical electrode with anti-microbial properties
WO2020212948A1 (en) 2019-04-17 2020-10-22 Compass Pathfinder Limited Methods of treating neurocognitive disorders, chronic pain and reducing inflammation
JP2022550463A (ja) 2019-10-01 2022-12-01 エンピリアン ニューロサイエンス， インコーポレイテッド トリプタミン発現を調整する真菌の遺伝子操作
DE102020106115A1 (de) 2020-03-06 2021-09-09 Lts Lohmann Therapie-Systeme Ag Iontophoretische Zusammensetzung zur Verabreichung von S-Ketamin
CN115916215A (zh) * 2020-04-16 2023-04-04 长矛治疗股份有限公司 迷幻剂衍生物的经皮微剂量递送
US20230219889A1 (en) 2020-05-19 2023-07-13 Cybin Irl Limited Deuterated tryptamine derivatives and methods of use
US11312684B1 (en) 2021-02-10 2022-04-26 Eleusis Therapeutics Us, Inc. Pharmaceutically acceptable salts of psilocin and uses thereof
CA3210966A1 (en) * 2021-02-10 2022-08-18 Eleusis Therapeutics Us, Inc. Pharmaceutically acceptable salts of psilocin and uses thereof
WO2022212789A1 (en) * 2021-03-31 2022-10-06 Mycrodose Therapeutics Inc. Transdermal system, formulation, and method for the therapeutic administration of a psychedelic agent
CA3220214A1 (en) * 2021-05-26 2022-12-01 Abdelmalik Slassi Hallucinogen-fatty acid combination

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US486902A (en) * 1892-11-29 Galvanic body-battery
US222276A (en) * 1879-12-02 Improvement in combined galvanic and medicated pad
CA1267937A (en) * 1984-10-29 1990-04-17 Joseph Bradley Phipps Iontophoretic drug delivery
CA2079315C (en) * 1990-03-30 2003-04-15 Joseph Bradley Phipps Device and method for iontophoretic drug delivery
DE4014913C2 (de) * 1990-05-10 1996-05-15 Lohmann Therapie Syst Lts Miniaturisiertes transdermales therapeutisches System für die Iontophorese
US5489624A (en) * 1992-12-01 1996-02-06 Minnesota Mining And Manufacturing Company Hydrophilic pressure sensitive adhesives
CA2126487C (en) * 1993-06-23 2001-05-29 Keiichiro Okabe Iontophoresis device
US6048545A (en) 1994-06-24 2000-04-11 Biozone Laboratories, Inc. Liposomal delivery by iontophoresis
CA2208332A1 (en) 1996-06-20 1997-12-20 Hisamitsu Pharmaceuticals Co., Inc. Drug administration composition for iontophoresis
GB9614098D0 (en) * 1996-07-05 1996-09-04 Orion Yhtymae Oy Transdermal delivery of levosimendan
DE19653606A1 (de) * 1996-12-20 1998-06-25 Roehm Gmbh Haft- und Bindemittel aus (Meth)acrylatpolymer, organischer Säure und Weichmacher
EP0898962A1 (en) 1997-08-28 1999-03-03 Becton, Dickinson and Company Transdermal patches and methods for inactivating skin proteases
US7258850B2 (en) * 1999-05-04 2007-08-21 Aradigm Corporation Methods and compositions for treating erectile dysfunction
JP4414517B2 (ja) * 1999-09-01 2010-02-10 久光製薬株式会社 イオントフォレーシス用デバイス構造体
US6496727B1 (en) * 2000-05-31 2002-12-17 Becton, Dickinson And Company Medicament-loaded transdermal reservoir and method for its formation
DE10035891A1 (de) * 2000-07-24 2002-02-14 Lohmann Therapie Syst Lts Medizinischer Haftkleber mit einer zweiphasigen Klebermatrix aus Polyacrylaten und Polyaminsalzen
DE10043321B4 (de) * 2000-08-24 2005-07-28 Neurobiotec Gmbh Verwendung eines transdermalen therapeutischen Systems zur Behandlung der Parkinsonschen Krankheit, zur Behandlung und Prävention des prämenstruellen Syndroms und zur Lactationshemmung
IT1319210B1 (it) * 2000-10-13 2003-09-26 Italiano Biochimico Lisapharma Pellicola per la somministrazione dermica e transdermica di principiattivi.
US6745082B2 (en) * 2001-10-22 2004-06-01 Jens Axelgaard Current-controlling electrode with adjustable contact area
JP4394444B2 (ja) * 2001-10-24 2010-01-06 パワー ペーパー リミティド 活性物質の制御された皮膚内デリバリーのためのデバイス及び方法
US6745071B1 (en) * 2003-02-21 2004-06-01 Birch Point Medical, Inc. Iontophoretic drug delivery system
RU2326893C2 (ru) 2003-04-16 2008-06-20 Кориум Интернэшнл Ковалентное и нековалентное сшивание гидрофильных полимеров и адгезивные композиции, полученные с ними
PT1670433E (pt) * 2003-10-10 2012-02-08 Ferring Bv Fórmula farmacológica transdérmica para a minimização de resíduos na pele
NZ610790A (en) * 2006-04-13 2015-05-29 Nupathe Inc Transdermal methods and systems for the delivery of anti-migraine compounds
EP2040794A4 (en) 2006-06-16 2010-10-20 Transport Pharmaceuticals Inc PHARMACEUTICAL FORMULATIONS FOR IONTOPHORETIC ADMINISTRATION OF TETRACYCLIN ANTIBIOTICS
EP2063863A2 (en) * 2006-08-29 2009-06-03 Alza Corporation Drug electrotransport with hydration measurement of hydratable reservoir
JP2010520885A (ja) * 2007-03-09 2010-06-17 チェルシー・セラピューティクス，インコーポレイテッド 線維筋痛症の治療のためのドロキシドパ及びその医薬組成物
US8366600B2 (en) * 2008-06-19 2013-02-05 Nupathe Inc. Polyamine enhanced formulations for triptan compound iontophoresis

Also Published As

Publication number Publication date
IL210080A0 (en) 2011-02-28
CN105456181A (zh) 2016-04-06
WO2009153019A1 (en) 2009-12-23
CN102046157A (zh) 2011-05-04
US20200113819A1 (en) 2020-04-16
JP2011524389A (ja) 2011-09-01
CA2728975C (en) 2016-06-07
RU2517241C2 (ru) 2014-05-27
RU2010150880A (ru) 2012-06-20
NZ590510A (en) 2012-08-31
BRPI0909936A2 (pt) 2015-10-20
KR101656537B1 (ko) 2016-09-09
IL210080A (en) 2016-03-31
ES2639576T3 (es) 2017-10-27
KR20110028361A (ko) 2011-03-17
JP2015007080A (ja) 2015-01-15
JP5620907B2 (ja) 2014-11-05
US10881606B2 (en) 2021-01-05
CA2728975A1 (en) 2009-12-23
EP2285362A1 (en) 2011-02-23
US10881607B2 (en) 2021-01-05
AU2009259601B2 (en) 2014-09-18
EP2285362B1 (en) 2017-08-09
MX2010013853A (es) 2011-03-15
US20110111029A1 (en) 2011-05-12
BRPI0909936B1 (pt) 2019-07-23
EP3308777A1 (en) 2018-04-18
AU2009259601A1 (en) 2009-12-23
PL2285362T3 (pl) 2017-12-29
ZA201007576B (en) 2011-08-31

Similar Documents

Publication Publication Date Title
MX351262B (es) Composicion para el transporte transdermico de agentes activos cationicos.
WO2012092628A3 (en) Patches and methods for the transdermal delivery of agents to treat hair loss
MX2022008277A (es) Composiciones de gel para administracion transdermica para maximizar las concentraciones de farmaco en el estrato corneo y suero, y metodos de uso de las mismas.
NZ608202A (en) Agent for treatment of dry eye characterized by combining p2y2 receptor agonist and hyaluronic acid or salt thereof, method for treating dry eye, and use of the p2y2 receptor agonist and hyaluronic acid or salt thereof
WO2012136969A3 (en) Ophthalmic treatments
MX2013006040A (es) Antagonistas del receptor de acido lisofosfatidico y su uso en el tratamiento de fibrosis.
MX2020012868A (es) Metodos y composiciones para trastornos del sue?o y otros trastornos.
MX2011013201A (es) Composiciones para tratar adiccion a drogas y para mejorar comportamiento relacionado a la adiccion.
IN2012DN02782A (es)
MX2013000001A (es) Composición farmaceutica de liberacion prolongada y acción retardada que comprende dapoxetina para administaracion oral.
MX337614B (es) Tratamiento de lupus nefritis usando laquinimod.
NZ703532A (en) Methods of treating arthritis
BR112014010586A2 (pt) aditivos para uso na preservação da madeira
GB2523715A (en) Transdermal delivery system
EP2490700A4 (en) EXTERNAL SKIN CARE COMPOSITION COMPRISING SALT AND SUGAR AS ACTIVE INGREDIENTS FOR PREVENTING AND TREATING VAGINOSIS AND USE THEREOF
AU2016216741A1 (en) Compositions and methods of use of an inappetance-controlling compound
MX342930B (es) Composicion reticuladora mejorada, suministrada por iontoforesis, util para el tratamiento de queratocono.
IL209270A (en) Compounds containing tricyclic nitrogen and their use as antibacterial
WO2007125383A3 (en) Topical drug delivery by iontophoresis
EP3295932A3 (en) Stable odf composition containing hardly soluble therapeutic agent
GB201009173D0 (en) Treatment of pain
MX2010006019A (es) Metodos para administrar acido ribonucleico pequeño de interferencia (arnsi) mediante iontoforesis.
HK1111924A1 (en) Depigmenting or brightening cosmetic composition comprising at least one oxazolin as an active ingredient
MX2015010967A (es) Formulaciones transdermicas de laquinimod.
MX365021B (es) Composicion para tratar o prevenir enfermedades ocasionadas por permeabilidad vascular, que contiene como ingrediente activo imatinib o una sal farmaceuticamente aceptable del mismo.

Legal Events

Date Code Title Description
FG Grant or registration